Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / MIF

MIF

Basics

Aliases:
This biomarker is also known as:
  • GIF,
  • MMIF,
  • Glycosylation-inhibiting factor,
  • phenylpyruvate tautomerase,
  • L-dopachrome isomerase,
  • macrophage migration inhibitory factor (glycosylation-inhibiting factor),
  • GLIF,
  • macrophage migration inhibitory factor,
  • L-dopachrome tautomerase,

View in BioMuta

Description…

MIF, a lymphokine involved in cell-mediated immunity, immunoregulation, and inflammation, plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoids. This lymphokine and the JAB1 protein form a complex in the cytosol near the peripheral plasma membrane, which may indicate an additional role in integrin signaling pathways. MIF is also closely related to tumorigenesis.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: MIF

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: One
QA State: Under Review

Overview

Reports have demonstrated that MIF expression is increased in premalignant, malignant, and metastatic tumors and a potential therapeutic target in NSCLC.

Performance Comment

Ovary

Attributes

Phase: Three
QA State: Curated

Overview

MIF RNAi significantly inhibited MIF expression in HO-8910 and OVCAR-3 cells and decreased cell proliferation of the two cells (P<0.05). Positive expression of MIF protein was detected in 53.5% of ovarian carcinoma tissues and was positively correlated to clinical stages of patients (P<0.01).

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. MIF alone was not a strong predictor.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.